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Abstract: The aim of this study was to test the combined effect of a quality-controlled red 
clover extract (RCE) standardized to contain 40% isoﬂ  avones by weight (genistein, daidzein, 
biochanin A, and formononetin present as hydrolyzed aglycones) together with a modiﬁ  ed 
alkaline supplementation on bone metabolic and biomechanical parameters in an experimental 
model of surgically-induced menopause. Sprague–Dawley female rats were maintained under 
controlled standard conditions of light and fed with conventional food of standard calcium 
content and no alfalfa or soybean components. Rats were randomized into four groups: Group A 
represented normal rats (sham operated) while three other groups were ovariectomized (OVX) 
and fed for three months as follows: standard food (group B), 6 mg/kg/day food mixed with 
RCE (Group C), or given 6 mg/kg/day of RCE plus a modiﬁ  ed alkaline supplementation (BP) 
through a nasogastric tube at a dose of 16 mg (group D). The animals were killed 90 days after 
surgery. As compared to group B, RCE or RCE + BP treatments brought about signiﬁ  cantly 
higher level of estradiol and mitigated the weight loss of the uterus and improved maximum load 
of the femoral neck. Osteocalcin level showed an over 65% increase in group B but both RCE and 
RCE + BP treatments prevented such abnormality with a signiﬁ  cantly better result in RCE + BP 
group which virtually normalized such parameter as well as urinary excretion of DPD. Group C 
and D reduced the over 20% loss of bone mineral density and bone mineral content/body weight 
ratio observed in untreated post-ovariectomy group. Untreated ovariectomy caused about 48% 
decrease of cancellous bone mass in the femoral neck while this abnormality was prevented at 
similar extent by both RCE and RCE + BP treatments. Ovariectomy determined an over 80% 
increase of bone alkaline phosphatase (BALP) level but both RCE and RCE + BP treatments 
signiﬁ  cantly mitigated such variable. The BALP decrease yielded by the combined RCE + BP 
treatment was statistically lower than RCE alone. Taken together these data show that red clover 
preparation in dosages amenable to clinical practice do improve OVX-induced osteoporosis 
while a mild metabolic alkalosis might further synergize some therapeutic aspects.
Keywords: red clover, alkaline supplementation, osteoporosis, ovariectomy
Introduction
Osteoporosis represents the most common metabolic bone disease1 and WHO deﬁ  nes it 
as a systematic skeletal disease characterized by low bone mass and micro-architectural 
deterioration of bone tissue, with a consequent increase in bone fragility and suscep-
tibility to fractures.2 The most common type of osteoporosis is the bone loss associ-
ated with menopausal ovarian hormone deﬁ  ciency. The incidence of osteoporosis is 
increasing worldwide as populations age and women are generally disproportionably 
affected by osteoporosis in developed countries and four times more likely than men to 
develop osteoporosis. Moreover, fracture rates among women are approximately twice 
as high as men.3 Indeed, estrogen deﬁ  ciency is regarded as a critical cause of osteopo-
rosis, which can result from naturally or surgically induced menopause and endocrine Clinical Interventions in Aging 2009:4 92
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disorders that reduce estrogen secretion in premenopausal 
women. It inﬂ  uences osteoclast which enhances bone loss 
by stimulating bone resorption. Convention therapies for 
treating osteoporosis in women include hormone replace-
ment therapy, either estrogen alone or in combination with 
progesterone, estrogen receptors-modulators, calcitonin and 
bisphosphonates.4
The Women’s Health Initiative initial study results dem-
onstrated a statistically signiﬁ  cant reduction in fractures, 
including hip fractures, in a large group of otherwise healthy 
women using hormone therapy. However, it also poses a 
number of cautions5 thus prompting active research to identify 
new agents for the treatment of postmenopausal osteoporosis 
with minimal side effects. Of all the natural alternatives cur-
rently under investigation, phytoestrogens appear to offer the 
most potential for the prevention of bone loss and they have 
attracted new attention as a possible agent to prevent and 
treat postmenopausal osteoporosis in women. From an epi-
demiological standpoint, Asian female population have lower 
rates of osteoporosis-related fractures than Western women6 
and, besides a likely different genomic proﬁ  le and different 
hip axis length, this is suspected to be in part because they 
consume more soy products such as miso and tofu that are rich 
in isoﬂ  avones, than Western women do.7,8 The evidence from 
both experimental in vivo and human studies have conﬁ  rmed 
that soy isoﬂ  avones favorably impact bone health.9
Although the potential beneﬁ  cial effects of a high phy-
toestrogen diet have been reported in some articles,10,11 only 
few articles are available on the potential impact of these 
compounds on osteoporosis treatment and/or prevention. 
The preventive effect of soybean protein on ovariectomized 
(OVX)-induced bone loss12 has been attributed to its high 
content of the isoﬂ  avones genistein and daidzein phytoes-
trogens which possess a range of biological effects including 
estrogenic, antiestrogenic, antiviral and antiproliferative 
actions.13
Red clover (Trifolium pratense L, Fabaceae) botanical 
dietary supplements have received much attention recently 
for their potential use in the treatment of menopause symp-
toms, maintenance/improvement cardiovascular health and 
for the reported benign effects on the breast, endometrium 
and neural structure besides for its safety.14–17 As for the bone-
preserving property, the effects of red clover have not been 
examined as extensively as for soy. Only three randomized 
controlled trials of red clover isoﬂ  avones for bone loss have 
been published but with two of them clearly demonstrating 
a positive effect on bone mineral density (BMD)18,19 as well 
as an increase in bone formation markers.
The ovariectomized rat is the most appropriate model 
for studying the mechanism as well as potential treatments 
of postmenopausal osteoporosis in humans. It is also a good 
model to study the efﬁ  cacy of a number of candidates for their 
prevention and/or reversal of bone loss.20 For instance, Dai and 
colleagues21 have very recently shown that genistein preserved 
the biomechanical quality of the vertebral trabecular bone 
regardless of the microstructure and BMD in ovariectomized 
rats although such experimental data have to be interpreted 
with caution in terms of humans applicability. Besides the 
important endocrine modulator of bone matrix, it has been 
shown that supplementation with alkaline salts have signiﬁ  -
cant effects on markers of bone turnover and urinary pH and 
net acid excretion.22–24 We have recently demonstrated that a 
balanced alkaline supplementation could signiﬁ  cantly prevent 
high protein-induced chronic acidosis with hypercalciuria and 
hyperphosphaturia25 while also improving muscular metabo-
lism under exhaustive exercise.26 Accordingly, animal and 
in vitro studies have clearly elucidated the mechanisms for 
the effect of metabolic acidosis on bone metabolism27,28 and 
have also established that metabolic acidosis is responsible 
for the effect of modiﬁ  ed pH on bone cells and that this effect 
is mediated by prostaglandin E2.29,30
Thus, the aim of this study was to test the combined effect 
of a quality-controlled red clover extract (RCE) standardized 
to contain 40% isoﬂ  avones by weight (genistein, daidzein, 
biochanin A, and formononetin present as hydrolyzed agly-
cones) together with a modiﬁ  ed alkaline supplementation on 
bone metabolic and biomechanical parameters in an experi-
mental model of surgically-induced menopause.
Materials and methods
Study protocol
Ninety-day-old Sprague–Dawley nulliparous female rats, 
with mean weight of 210 g, were selected and were acclima-
tized for 2 weeks under controlled standard conditions of light 
(12/24 h) and temperature (26 ± 1 °C). Food pellets (without 
any alfalfa or soybean components and with standard 0.44% 
calcium content which was slightly reduced in treated groups 
so to compensate with the calcium contained in the alkaline 
supplementation) and tap water were provided ad libitum. 
For experimental purposes animals fasted overnight but were 
allowed free access to water. All animal procedures were 
performed according to approved protocols and in accordance 
with the recommendations for the proper care and use of 
laboratory animals. Eighty rats were randomized into four 
groups of 20 animals each. Group A represented normal rats 
(sham operated) while three other groups underwent bilateral Clinical Interventions in Aging 2009:4 93
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ovariectomy (OVX) under isoﬂ  urane anaesthesia and fed 
from the following day as follows. One OVX group was 
kept on standard food (group B) while the remaining two 
OVX groups of rats were started on a different daily feeding 
for 3 months as follows: Group C was fed with 6 mg/kg/day 
food mixed with RCE (Menoﬂ  avon Forte®, Named, Lesmo, 
Italy). This dose was chosen on the basis of prior in-house 
dose-response test and aiming to be not too different from 
the one commonly used in clinics (240 mg/day). Group D 
was given 6 mg/kg/day of RCE plus a modiﬁ  ed alkaline 
supplementation through a nasogastric tube at a dose of 16 mg 
(BP: calcium bicarbonate, sodium bicarbonate, magnesium 
and potassium carbonate, and bisodium phosphate). At the 
end of the experimental period, the animals were fast over-
night, and sacriﬁ  ced by cervical dislocation while the blood 
being collected from the carotid artery. The serum obtained 
by centrifugal separation was stored at −30 °C until assay. 
The animals were killed 90 days after surgery and the femurs 
were removed to carry out the below-mentioned studies.
Serum estradiol and osteocalcin
Serum estradiol was assayed by a direct radioimmunoassay 
kit (n. 0355, Hindawi-Tech, Bangalore, India) The antibody 
used was #244 anti-estradiol-6-BSA serum at a dilution 
of 1:3,000. Intra- and interassay CV were 12% and 11%, 
respectively.
Serum osteocalcin was determined by a species-speciﬁ  c31 
RIA kit with rat 125I-labeled OC, goat anti-rat osteocalcin 
antibody (Biochemical Technologies, Stoughton, MA, USA). 
using a gamma counter (Hewlett-Packard, Palo Alto, CA, 
USA) where the analytic kit recognizes also the N-terminal 
midfragment thus allowing the correction of potential degra-
dation of the intact molecule. The intra- and interassay coef-
ﬁ  cients of variation were below 4.5% and 7%, respectively, 
and the sensitivity is 0.54 ng/mL.
Determination of uterine weight
At necropsy, the uteri were collected, trimmed of fat and 
connective tissue, cut open and drained of intrauterine ﬂ  uid, 
weighed, frozen in 1.5-mL cryogenic vials on dry ice, and 
stored at −70 °C until analysis.
Bone mineral and cancellous 
bone mass assessment
Bone densitometry of the whole femur was performed with 
Dual-Energy X-Ray Absorption (DEXA) scanner (GE-Lunar 
Corp., Madison, WI, USA) running software version 1.45 
equipped with a high resolution for the evaluation of bone 
mineral in small subjects. Both bone mineral content (BMC) 
and BMD were determined, the former calculated as absolute 
value and in relationship with body mass too. The coefﬁ  cient 
of variation for total BMD as measured in prior in-house tests 
is 1.0% ± 0.3% and scan acquisition time was 5 min/animal
For cancellous bone mass analysis, the proximal femur 
was sawed off, stained with Villaneuva stain, defatted and 
embedded undecalciﬁ  ed in methyl methacrylate. Longitu-
dinal bone sectioning was then started at approximately one 
third the depth of the femoral neck with a microtome set at 
4 μm thickness sections. The percentage of cancellous bone 
mass (BV/TV) was measured with a computer-linked light 
microscope from the entire cancellous spongiosa of the 
proximal femur in a standardized mid region 1 mm distal to 
the growth plate–metaphyseal junction.
Measurement of bone mechanics
Bones were kept in NaCl (9 g/l) at 4 °C until whole left 
femoral breaking force was determined 24 h afterwards with 
three-point loading. Prior to mechanical testing, the left femurs 
were slightly thawed and held at room temperature on the day 
of test, then connective tissues were carefully removed, the 
length of the femurs was measured with a micrometer. The 
load was applied perpendicularly to the long axis of the femur 
in the mid-length of the bone supported on its epiphyses. 
The load increased at a rate of 100 N/min. The load was 
measured by the sensor with a strain gauge; the deformation 
was measured by an inductive sensor. The signals sent by the 
sensors were ampliﬁ  ed and registered. The load-deformation 
curves, obtained for each bone, representing the relationships 
between load applied to the bone and deformation in response 
to the load, were analyzed. The load-deformation curve can 
be divided into the elastic deformation region and the plastic 
deformation region. Within the elastic deformation region, 
the slope of the linear part of the load-deformation curve, 
representing the extrinsic stiffness of bone, was tested. Within 
the plastic deformation region, the ultimate load and the break-
ing load were determined. The ultimate load is the maximum 
load sustained by the bone. The breaking load is the load at 
which the bone actually breaks. The force and energy (area 
under the curve, N3 mm) necessary for the break at the center 
of the femur shaft were measured. Deformation caused by the 
applied loads was also measured. The mechanical strength 
of the left femoral neck was determined using a compression 
test with the same instrument. In femur shaft mechanical 
test, all femoral specimens were broken into two pieces, the 
proximal part was used and embedded in resin up to the lesser 
trochanter and a cylinder was shaped. The sample was inserted Clinical Interventions in Aging 2009:4 94
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into a steel support in a vertical orientation. The mechanical 
resistance to failure was tested by applying a vertical load on 
the femoral head at a speed of 2 mm/min. All mechanic tests 
data were expressed as Newton (N).
Total (TALP) and bone-speciﬁ  c (BALP) 
alkaline phosphatase and urinary 
deoxypyridinoline assay
Total alkaline phosphatase (TALP) was measured spectropho-
tometrically on a using p-nitrophenyl phosphate as substrate. 
The intra-assay CV was 1.9% and the inter-assay CV 2.8% at a 
mean value of 482 μ/l. For bone alkaline phosphatase (BALP) 
assay the samples were pretreated by incubating 300 μl of 
serum with 30 μl Triton X (20 g/l) for 30 min at 37 °C. An 
aqueous solution of wheat germ lectin (300 μl Sigma-9640, 
5 g/l in distilled water) was then added, and the samples were 
mixed and incubated for 30 min at 37 °C. After centrifugation 
at 2000 g for 10 min, the alkaline phospatase activity in the 
supernatant was determined as above, and calculated as the dif-
ference between total and supernatant activity after correction 
for sample dilution. This was measured spectrophotometrically 
in the supernatant after precipitation with wheat germ lectin. 
The intra-assay CV was 5.3% and the inter-assay CV 6.1% at a 
mean value of 240 μ/l. Urinary deoxypyridinoline (DPD) excre-
tion was determined by competitive radioimmunoassay with rat 
monoclonal anti-DPD antibody coated to the inner surface of a 
polystyrene tube and 125I-labeled DPD (DPD-uri kit, Hindawi-
Tech, Bangalore, India). The sensitivity was 2.5 nmol/L. The 
intra- and interassay variations were 5% and 8%, respectively. 
Results were expressed as nmol DPD/mmol creatinine.
Statistical analysis
All data were expressed as means ± standard deviation. 
Statistical analysis was done using StatView J-4.5 (Abacus 
Concepts Inc., Berkeley, CA, USA). Signiﬁ  cance of the 
results was determined by one-way analysis of variance 
(ANOVA) and Bonferroni analysis was applied to test 
the differences between individual groups. A p value   0.05 
was considered statistically signiﬁ  cant.
Results
RCE and BP supplementation did not cause any overt side 
effects and the histology and mass of the internal organs 
examined (liver, kidney, spleen, pancreas and heart) were 
within normal limits (data not shown). Group B OVX rats 
showed an almost 45% gain of body mass increase as com-
pared to sham-operated rats (group A) (p   0.01, data not 
shown) but this effect was signiﬁ  cantly reduced to less than 
30% in both treatment groups (C and D vs B, p   0.05). 
During our experiment, no signiﬁ  cant difference was found 
among the various groups, ovariectomy did not affect the 
femur and tibia length compared to the sham rats. Treatment 
with either RCE and RCE + BP did not inﬂ  uence the growth 
rates of these long bones (data not shown).
Effects of ovariectomy, RCE, and RCE + 
BP supplementation on serum estradiol, 
osteocalcin levels, and uterine weight
As compared to OVX group devoid of any speciﬁ  c supple-
ment (group B), RCE or RCE + BP treatment brought about 
a comparably and signiﬁ  cantly higher level of estradiol 
(p   0.05) although this resulted about 30% lower than in 
sham-operated rats (group A) (p   0.05, Figure 1A). Ovari-
ectomy brought about a decrease of over 70% of the uterus 
weight (p   0.01). Such loss was signiﬁ  cant less pronounced 
when OVX rats were given RCE or RCE + BP (p   0.05 
vs group B) although it was still about 50% lower that in 
the sham-operated rats (p   0.01, Figure 1B). Osteocalcin 
level showed an over 65% increase in untreated OVX rats 
(group B) as compared to sham-operated ones (group A). 
Both RCE and RCE + BP treatments remarkably prevented 
such abnormality (C and D vs B, p   0.01, Figure 1C) with a 
signiﬁ  cantly better result in RCE + BP group which virtually 
normalized such parameter ( 25% vs C, p   0.05).
Bone mineral and cancellous 
bone mass assessment
Daily supplementation of OVX rats with RCE or RCE + BP 
reduced the over 20% loss of BMD observed in untreated 
post-ovariectomy group (C and D vs B, p   0.05, Figure 2A). 
Combined treatment with RCE and BP (group D) showed a 
trend better value ( 9% vs group C ) but this did not reach 
a statistical signiﬁ  cance. BMC as absolute value was not 
affected by ovariectomy nor by treatments (data not shown). 
However, when calculated in relationship with body mass, 
it appeared a signiﬁ  cant decrease of this parameters in rats 
which had underwent ovariectomy and fed standard food 
(group B) (p   0.05, Figure 2B). Such abnormality was 
abolished by the concomitant treatment with either treatment 
employed (p   0.05 vs group B). Untreated ovariectomy 
(group B) caused about 48% decrease of cancellous bone 
mass in the femoral neck as compared to sham-operated rats 
(p   0.01, Figure 2C) while this abnormality was prevented 
at similar extent by both RCE and RCE + BP treatments 
(p   0.05 vs group B).Clinical Interventions in Aging 2009:4 95
Phytoestrogen and alkalinization in osteoporotic ovariectomized rats
0
20
40
60
80
100
120
140
pg/ml
A Estradiol level
*
** **
0
100
200
300
400
500
mg
B Uterus weight
**
*
0
0.05
0.1
0.15
0.2
0.25
0.3
C Osteocalcin level
ng/ml
*
**
** #
D C B A
D C B A
D C B A
**
Figure 1 Effect of ovariectomy and supplementation of RCE and RCE + BP on estradiol A) uterine weight B) and osteocalcin level C) (mean ± SD).
Notes: *p   0.01 vs sham-operated (group A); **p   0.05 vs untreated ovariectomy rats (group B), #p   0.05 vs group C (RCE-treated OVX rats).
Abbreviations: BP, calcium bicarbonate, sodium bicarbonate, magnesium and potassium carbonate, and bisodium phosphate; OVX, ovariectomized; RCE, red clover extract.Clinical Interventions in Aging 2009:4 96
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Figure 2 Effect of ovariectomy and supplementation of RCE and RCE + BP on bone mineral density A) bone mineral content/body wt ratio B) and cancellous bone mass C) 
(mean ± SD).
Notes: *p   0.01 vs sham-operated (group A); **p   0.05 vs untreated ovariectomy rats (group B); #p   0.05 vs group C (RCE-treated OVX rats).
Abbreviations: BP, calcium bicarbonate, sodium bicarbonate, magnesium and potassium carbonate, and bisodium phosphate; OVX, ovariectomized; RCE, red clover extract.Clinical Interventions in Aging 2009:4 97
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Measurement of bone mechanics
Mechanical testing of femoral necks showed that ovariecto-
mized rats, whether specially supplemented or not, did not 
cause any signiﬁ  cant change in energy absorption and stiff-
ness, although RCE + BP-treated rats showed a not signiﬁ  -
cant trend improvement as compared to group B. Moreover, 
no change among groups appeared in the deformation or 
breaking parameters measured by three point bending tests 
(data not shown). On the other hand untreated ovariectomy 
(group B) brought about a signiﬁ  cant decrease of the maximal 
load of the femoral neck when compared to the sham rats 
(p   0.01, Figure 3). Either treatment of RCE (group C) or 
RCE + BP (group D) proved to be effective in totally pre-
serving such mechanical failure. No signiﬁ  cant difference 
appeared between these two therapeutic regimens.
Effects of RCE or RCE + BP 
and ovariectomy on serum TALP, 
BALP, and urinary DPD
As expected OVX rats showed a signiﬁ  cant decrease of 
TALP (p   0.05) but no statistically signiﬁ  cant differ-
ence appeared among the two different treatment groups 
(data not shown). Ovariectomy determined an over 80% 
increase of BALP level (p   0.01, Figure 4) but both RCE 
and RCE + BP treatment mitigated such value to 15%–35% 
increase (p   0.01, Figure 4). Further, the BALP decrease 
yielded by the combined RCE + BP treatment (group D) was 
about 16% lower than RCE alone (group C) and this was 
statistically signiﬁ  cant (p   0.05). Moreover, untreated OVX 
rats (group B) showed a remarkable increase of over 58% of 
urinary excretion of DPD (group B vs A, p   0.05) while 
such parameter was within normal limits in both treatments 
groups (p   0.05 vs group B).
Discussion
Osteoporosis is the most common metabolic bone dis-
ease associated with disharmonic bone remodeling due to 
decreased bone formation or accelerated bone resorption. Its 
regulators are changed by age, ions, hormones and growth 
factors.33–35 In the western world, the prevalence of osteopo-
rosis and osteopenia in those aged 55 to 64 years is 20% and 
37%, respectively. This represents now a major public health 
threat, and its prevalence is expected to rise dramatically in 
the coming decades.36,37 Estrogens play an important role 
in skeletal homeostasis, and ovarian hormone deﬁ  ciency is 
one of the most important risk factors for osteoporosis. Bone 
loss is most rapid in the ﬁ  rst few years after menopause but 
it may persist into the postmenopausal years. Because of 
their selective estrogenic like activity, soy and red clover 
have been hypothesized to have a positive effect on bone 
mineral density as women age. There are clear bone-related 
beneﬁ  ts of hormone replacement therapy, but given the 
uncertain popularity of this approach there is a clinical need 
for alternative well tolerated pharmacological or nutritional 
treatments that can safely be used soon after the menopause 
and which effectively prevent bone loss and the development 
of osteoporosis. Phytoestrogens such as those derived from 
red clover may help with hot ﬂ  ushes, which are a common 
menopausal complaint. Red clover isoﬂ  avones have more 
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Figure 3 Effect of ovariectomy and supplementation of RCE and RCE + BP on maximal load on femoral neck (mean ± SD).
Notes: *p   0.01 vs sham-operated (group A); **p   0.05 vs untreated ovariectomy rats (group B).
Abbreviations: BP, calcium bicarbonate, sodium bicarbonate, magnesium and potassium carbonate, and bisodium phosphate; OVX, ovariectomized; RCE, red clover extract.Clinical Interventions in Aging 2009:4 98
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evidence-based studies than most herbal medicinal products, 
although the literature is beset by difference in methodolo-
gies making direct comparison between them difﬁ  cult. In 
the present study we employed dosages of red clover which 
are amenable to clinical practice application and found that 
such supplementation proved to be effective in increasing 
the BMD and BMC together with counteracting the drastic 
decrease of cancellous bone mass due to OVX.
It has been reported that both bone resorption and 
bone formation are promoted by ovariectomy.38 Estrogen 
induces a decrease in bone resorption and may also have 
some anabolic effect, particularly in high doses in post-
menopausal women at all ages.39,40 Treatment with RCE 
showed to signiﬁ  cantly mitigate the post-OVX fall of 
estradiol level which partly maintained their trophic effect 
also on the uterine tissue. It is well known that the body’s 
acid–base balance plays an important role in bone health 
and is modiﬁ  able by diet.41,42 Indeed, the organic acids which 
are produced during metabolism and the hepatic oxidation 
of sulfur-amino acids lower blood pH through increased 
production of hydrogen ions.43 We have recently shown that, 
by employing the same modiﬁ  ed alkaline supplementation 
used in this study, it could prevent the chronic acidosis-
induced BMD loss with increased urinary output of DPD, 
calcium, and phosphorus in male rats fed an acidogenic 
high-protein diet.25 In daily life, the alkaline dietary 
components such as potassium, calcium, and magnesium 
act as physiological buffers for organic acids. However, 
if insufﬁ  cient levels of buffering capacity are available 
from alkaline salts, mild metabolic acidosis may subtly 
ensue even in healthy people, especially women44 with all 
the related bone derangement on the long run.42,45,56 In the 
present study, the addition of BP to RCE proved to further 
improve bone turnover markers such as urinary excretion of 
DPD, BALP,47 and serum osteocalcin. Osteocalcin is unique 
to bone tissue and it is the most abundant in noncollagenous 
bone protein. It is formed in the osteoblast and deposited 
in bone matrix although a small fraction of the newly syn-
thesized component is released into the bloodstream while 
its activity and synthesis increase when BMD is decreased 
due to higher bone resorption.48 In agreement with what 
was recently reported by Occhiuto and colleagues,49 who 
used larger dosages of red clover isoﬂ  avones, the mechani-
cal testing showed a signiﬁ  cant preservation of maximal 
load applied to the femoral neck in rats treated with RCE 
although either energy, stiffness, and deformation were not 
affected by OVX nor further improved by treatment. Dif-
ferent dosage and longer observation time might be factors 
to be taken into account in further studies when assessing 
such speciﬁ  c variables.
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Figure 4 Effect of ovariectomy and supplementation of RCE and RCE + BP on urinary DPD excretion and bone-speciﬁ  c ALP.
Notes: *p   0.01 vs sham-operated (group A); **p   0.05 vs untreated ovariectomy rats (group B); #p   0.05 vs group C (RCE-treated OVX rats).
Abbreviations: ALP, alkaline phosphatase; BP, calcium bicarbonate, sodium bicarbonate, magnesium and potassium carbonate, and bisodium phosphate; OVX, ovariectomized; 
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Although the ovariectomized rat is widely used as a model 
of postmenopausal osteoporosis a number of cautions have 
to be considered when assessing its relevance in clinics,50 
genetic differences with humans included. Nonetheless, 
the present ﬁ  nding show that RCE preparation employed 
at dosages not far from the ones applied in clinical practice 
are effective in reducing ovariectomy-induced bone loss by 
reducing bone turnover via inhibition of bone resorption and 
this effects might be further enhanced by a mild alkaliniza-
tion. Speciﬁ  c supplemental administration rather than dietary 
implementation seems to be a more deﬁ  ned approach with 
therapeutic modality without any reported negative effect 
while experimental studies are awaited in male osteoporosis 
given the increasing interest in estrogen receptor modulators 
also in male osteopenia.
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